firmonertinib
AssetAlso AFU, AST-2818
Inhibits epidermal growth factor receptor with exon 20 insertion mutations.
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- EGFR
- 3
- Indications
- 0
- Trials
- 1
- Developer
Indications
3Lung cancer
Phase 3, endpoints.news, 6 Oct 2026
Non-small cell lung cancer
Phase 3, globenewswire.com, 6 Oct 2026
Non-squamous non-small cell lung cancer
Phase 3, globenewswire.com, 6 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Evidence for its targets1
- Competitors8
Every asset’s record: target, stage, trials and the evidence behind it.